论文部分内容阅读
目的:观察前列清巴布贴外治慢性非细菌性前列腺炎的临床疗效。方法:将120例慢性非细菌性前列腺炎患者随机分为治疗组、对照Ⅰ组、对照Ⅱ组,分别给予口服舍尼通加前列清巴布贴外治、口服舍尼通加前列安栓外治、单纯口服舍尼通治疗1个月。观察治疗前后各组患者NIH-CPSI评分、前列腺液参数,判断其临床疗效。结果:治疗组总有效率为92.3%,比对照Ⅰ组和对照Ⅱ组均有优势(P<0.01);对照Ⅰ组优于对照Ⅱ组(P<0.05)。在改善前列腺液参数、降低NIH-CPSI症状积分方面,治疗组优于对照Ⅰ组和对照Ⅱ组(P<0.05)。结论:前列清巴布贴外治慢性前列腺炎有较好的临床疗效,比单用西药效果更好。
Objective: To observe the clinical effect of Qianlieqingbubian external chronic non-bacterial prostatitis. Methods: A total of 120 patients with chronic non-bacterial prostatitis were randomly divided into treatment group, control group Ⅰ and control group Ⅱ, and were given ciclopirox orally, Treatment, simple oral administration of Zenitone for 1 month. The NIH-CPSI score and prostatic fluid parameters of each group before and after treatment were observed to determine the clinical efficacy. Results: The total effective rate in the treatment group was 92.3%, which was superior to the control group Ⅰ and the control group Ⅱ (P <0.01). The control group Ⅰ was superior to the control group Ⅱ (P0.05). The treatment group was better than the control group Ⅰ and the control group Ⅱ (P <0.05) in improving prostatic fluid parameters and reducing NIH-CPSI symptom score. Conclusion: Qianlieqingbubu sticking outside the treatment of chronic prostatitis has a better clinical efficacy, better than single Western medicine.